Matt Abernethy

Companies

• Fate TherapeuticsBoard member May 30, 2025 to now¹
• Neurocrine BiosciencesChief financial officer Dec 5, 2017 to now²

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• Neurocrine Biosciences NBIX42,808 shares³$5.9M at $137.36Sep 14, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

• Sep 14, 2026Sold 2,311 shares at $157.20 of Neurocrine Biosciences³
• Sep 11, 2026Shares withheld for tax 2,709 shares at $156.22 of Neurocrine Biosciences³
• Sep 11, 2026Granted 5,020 shares of Neurocrine Biosciences³
• Mar 4, 2026Gift 2,249 shares of Neurocrine Biosciences⁴
• Feb 13, 2026Shares withheld for tax 5,378 shares at $124.12 of Neurocrine Biosciences⁵
• Feb 13, 2026Granted 9,968 shares of Neurocrine Biosciences⁵
• Feb 13, 2026Shares withheld for tax 1,385 shares at $124.12 of Neurocrine Biosciences⁵
• Feb 13, 2026Exercised options 2,566 shares of Neurocrine Biosciences⁵
• Feb 13, 2026Shares withheld for tax 1,210 shares at $124.12 of Neurocrine Biosciences⁵
• Feb 13, 2026Exercised options 2,241 shares of Neurocrine Biosciences⁵
• Feb 12, 2026Shares withheld for tax 1,151 shares at $123.10 of Neurocrine Biosciences⁵
• Feb 12, 2026Exercised options 2,133 shares of Neurocrine Biosciences⁵
• Jan 31, 2026Shares withheld for tax 1,368 shares at $136.06 of Neurocrine Biosciences⁶
• Jan 31, 2026Exercised options 2,437 shares of Neurocrine Biosciences⁶
• Feb 13, 2025Sold 1,206 shares at $116.87 of Neurocrine Biosciences⁷
• Feb 13, 2025Exercised options 2,241 shares of Neurocrine Biosciences⁷
• Feb 13, 2025Sold 1,352 shares at $116.85 of Neurocrine Biosciences⁷
• Feb 13, 2025Exercised options 2,566 shares of Neurocrine Biosciences⁷
• Feb 10, 2025Sold 980 shares at $118.27 of Neurocrine Biosciences⁸
• Feb 8, 2025Exercised options 1,860 shares of Neurocrine Biosciences⁸
• Jan 31, 2025Sold 1,283 shares at $152.87 of Neurocrine Biosciences⁹
• Jan 31, 2025Exercised options 2,436 shares of Neurocrine Biosciences⁹
• Aug 13, 2024Sold 14,100 shares at $150.38 of Neurocrine Biosciences¹⁰
• Aug 13, 2024Exercised options 14,100 shares at $73.60 of Neurocrine Biosciences¹⁰
• Jul 16, 2024Sold 900 shares at $150.04 of Neurocrine Biosciences¹¹